Payment overview · 2025
General Payments
$161.59
7 reported records · 2 companies
Healthcare provider profile · identity verified
Mayelin Morales, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · HOMESTEAD, FL · NPI 1457817058
Verified facts
What the public records show
CMS Open Payments records show Mayelin Morales, ARNP received $161.59 in general payments during 2025 across 7 reported records.
Sumitomo Pharma America, Inc. accounted for 58.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $94.60 | 58.5% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $66.99 | 41.5% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $161.59 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $94.60 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $24.59 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $21.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 76 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
76 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 735 | 282 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 437 | 171 |
| Losartan Potassium | Losartan Potassium | 404 | 140 |
| Metformin Hcl | Metformin Hcl | 401 | 141 |
| Gabapentin | Gabapentin | 370 | 134 |
| Diclofenac Sodium | Diclofenac Sodium | 340 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 328 | 105 |
| Lisinopril | Lisinopril | 324 | 121 |
| Pantoprazole Sodium | Pantoprazole Sodium | 300 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 234 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 228 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 183 | 71 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 163 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 162 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 160 | 61 |
| Azithromycin | Azithromycin | 157 | 130 |
| Omeprazole | Omeprazole | 156 | 66 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 147 | 34 |
| Famotidine | Famotidine | 143 | 65 |
| Glipizide | Glipizide | 133 | 56 |
| Eliquis | Apixaban | 131 | 33 |
| Montelukast Sodium | Montelukast Sodium | 130 | 56 |
| Alendronate Sodium | Alendronate Sodium | 126 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 123 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 123 | 38 |
| Januvia | Sitagliptin Phosphate | 120 | 29 |
| Memantine Hcl | Memantine Hcl | 117 | 44 |
| Furosemide | Furosemide | 111 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 43 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 99 | 44 |
| Mirtazapine | Mirtazapine | 93 | 39 |
| Carvedilol | Carvedilol | 91 | 32 |
| Azelastine Hcl | Azelastine Hcl | 88 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 32 |
| Allopurinol | Allopurinol | 81 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 34 |
| Farxiga | Dapagliflozin Propanediol | 76 | 23 |
| Simvastatin | Simvastatin | 76 | 34 |
| Mupirocin | Mupirocin | 73 | 37 |
| Nifedipine Er | Nifedipine | 71 | 25 |
| Methylprednisolone | Methylprednisolone | 65 | 55 |
| Trazodone Hcl | Trazodone Hcl | 65 | 29 |
| Lactulose | Lactulose | 64 | 21 |
| Ezetimibe | Ezetimibe | 60 | 19 |
| Baclofen | Baclofen | 58 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 33 |
| Ibuprofen | Ibuprofen | 57 | 34 |
| Tadalafil | Tadalafil | 55 | 17 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 54 | suppressed |
| Folic Acid | Folic Acid | 52 | 24 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 50 | 15 |
| Meloxicam | Meloxicam | 49 | 20 |
| Sertraline Hcl | Sertraline Hcl | 48 | 18 |
| Atenolol | Atenolol | 47 | 19 |
| Latanoprost | Latanoprost | 47 | 14 |
| Enalapril Maleate | Enalapril Maleate | 45 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 14 |
| Jardiance | Empagliflozin | 44 | suppressed |
| Ketoconazole | Ketoconazole | 44 | 16 |
| Novolog Flexpen | Insulin Aspart | 44 | suppressed |
| Celecoxib | Celecoxib | 43 | 19 |
| Finasteride | Finasteride | 43 | 17 |
| Glimepiride | Glimepiride | 43 | 14 |
| Sildenafil Citrate | Sildenafil Citrate | 43 | 16 |
| Clonidine Hcl | Clonidine Hcl | 42 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 16 |
| Tradjenta | Linagliptin | 41 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 40 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | 17 |
| Ammonium Lactate | Ammonium Lactate | 39 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 20 |
| Entresto | Sacubitril/Valsartan | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 38 | 16 |
| Humalog Kwikpen U-100 | Insulin Lispro | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 33 |
| Pentoxifylline | Pentoxifylline | 36 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 14 |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 35 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | 13 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 33 | 12 |
| Sure Comfort Alcohol | Alcohol Antiseptic Pads | 32 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 31 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 31 | 18 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 29 | 11 |
| Donepezil Hcl | Donepezil Hcl | 28 | 12 |
| Silver Sulfadiazine | Silver Sulfadiazine | 28 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 27 | 12 |
| Bumetanide | Bumetanide | 26 | suppressed |
| Nystatin | Nystatin | 26 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 25 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 22 |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Valsartan | Valsartan | 24 | 11 |
| Spironolactone | Spironolactone | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | 16 |
| Alprazolam | Alprazolam | 22 | 12 |
| Glipizide Er | Glipizide | 22 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Potassium Chloride | Potassium Chloride | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 19 |
| Naproxen | Naproxen | 21 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Ssd | Silver Sulfadiazine | 21 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 16 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 15 |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Lumigan | Bimatoprost | 16 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 15 |
| Cilostazol | Cilostazol | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Permethrin | Permethrin | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $161.59 · 7 records | Sumitomo Pharma America, Inc. | AIRSUPRA, FARXIGA, GEMTESA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error